Roche’s Elecsys IL-6 test receives FDA EUA
July 1, 2020—Roche announced that the FDA has issued an emergency use authorization for the Elecsys IL-6 test
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Invitae to acquire ArcherDX for $1.4 billion
June 30, 2020—Invitae and ArcherDX have entered into a definitive agreement under which the two companies will combine to create a cancer genetics and precision oncology company.
Sysmex America launches XF-1600 automated flow cytometer
June 26, 2020—Sysmex America announced the availability of its XF-1600 automated flow cytometer.
Simplexa Congenital CMV Direct kit gets CE mark
June 24, 2020—DiaSorin Molecular announced it has received the CE mark for its Simplexa Congenital CMV Direct kit.
Randox unveils cytokine tests
June 22, 2020—Randox Laboratories has unveiled cytokine testing for COVID-19 risk stratification and treatment monitoring.
Illumina receives EUA for sequencing-based COVID-19 dx
June 12, 2020—Illumina announced that the FDA issued an emergency use authorization for the Illumina COVIDSeq test, a high-throughput, sequencing-based, in vitro diagnostic workflow enabling the detection of SARS-CoV-2.
Randox ToRCH quality controls get CE mark
June 10, 2020—Randox Laboratories ToRCH quality controls for infectious disease testing in newborns have been granted the CE mark.
NeuMoDx introduces high-vol nucleic acid extraction capability
June 8, 2020—NeuMoDx Molecular released software that introduces “extraction only” capabilities among other enhancements.
FDA approves Opdivo + Yervoy, chemo for metastatic NSCLC
June 5, 2020—The Food and Drug Administration approved the combination of nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, BMS)
Qiagen introduces novel solutions in oncology
June 4, 2020—Qiagen announced the launch of novel solutions designed to enable faster, better analysis of genomic variations in cancer